


Please type a plus sign (+) inside this box → ☐



PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                       |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO   |   |    |   | <b>Complete if Known</b> |                       |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    |   | Application Number       | 09/981,289            |
|   |   |    |   | Filing Date              | October 15, 2001      |
|   |   |    |   | First Named Inventor     | DAHIYAT, Bassil I.    |
|   |   |    |   | Group Art Unit           | 1647                  |
|   |   |    |   | Examiner Name            | T. Seharaleyon        |
| Sheet   | 1 | of | 4 | Attorney Docket Number   | A-68990-3/RFT/RMS/RMK |

| U.S. PATENT DOCUMENTS |                       |                      |                                   |   |  |   |
|-----------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | U.S. Patent Document |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|                       |                       | Number               | Kind Code <sup>2</sup> (if known) |   |  |   |
| JR                    | A1                    | 4,677,063            |                                   | Mark et al.                                     | 06-1987  |   |
|                       | A2                    | 4,677,064            |                                   | Mark et al.                                     | 06-1987  |   |
|                       | A3                    | 4,879,226            |                                   | Wallace et al.                                  | 11-1989  |   |
|                       | A4                    | 4,894,439            |                                   | Dorin et al.                                    | 01-1990  |   |
|                       | A5                    | 4,948,875            |                                   | Tanaka et al.                                   | 08-1990  |   |
|                       | A6                    | 4,990,455            |                                   | Yamagishi et al.                                | 02-1991  |   |
|                       | A7                    | 5,028,420            |                                   | Masegi et al.                                   | 07-1991  |   |
|                       | A8                    | 5,081,021            |                                   | Mizuno et al.                                   | 01-1992  |   |
|                       | A9                    | 5,151,349            |                                   | Tanaka et al.                                   | 09-1992  |   |
|                       | A10                   | 5,160,483            |                                   | Postlethwaite et al.                            | 11-1992  |   |
|                       | A11                   | 5,180,811            |                                   | Doerper et al.                                  | 01-1993  |   |
|                       | A12                   | 5,262,309            |                                   | Nakamura et al.                                 | 11-1993  |   |
|                       | A13                   | 5,288,852            |                                   | Yamada et al.                                   | 02-1994  |   |
|                       | A14                   | 5,422,104            |                                   | Fiers et al.                                    | 06-1995  |   |
|                       | A15                   | 5,478,925            |                                   | Wallach et al.                                  | 12-1995  |   |
|                       | A16                   | 5,512,544            |                                   | Wallach et al.                                  | 04-1996  |   |
|                       | A17                   | 5,597,899            |                                   | Banner et al.                                   | 01-1997  |   |
| ✓                     | A18                   | 5,606,023            |                                   | Chen et al.                                     | 02-1997  |   |

RECEIVED

MAY 15 2002

TECH CENTER 1600/2100

COPY OF PAPERS  
ORIGINALLY FILED

| FOREIGN PATENT DOCUMENTS |                       |                         |                     |                                   |   |  |   |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|                          |                       | Office <sup>3</sup>     | Number <sup>4</sup> | Kind Code <sup>5</sup> (if known) |   |  |   |
| JR                       | B1                    | EP                      | 0 254 647           | A2                                | MITSUBISHI CHEM. IND.,                          | 01-1988  |   |
|                          | B2                    | EP                      | 0 486 908           | A3                                | F. HOFFMANN-LA ROCHE                            | 05-1992  |   |
|                          | B3                    | WO                      | 98/47089            | A1                                | CALIFORNIA INSTITUTE                            | 10-1998  |   |
|                          | B4                    | WO                      | 00/23564            | A2                                | XENCOR, INC.                                    | 04-2000  |   |
|                          | B5                    | WO                      | 01/25277            | A1                                | MAXYGEN APS                                     | 04-2001  |   |
|                          | B6                    | CA                      | 2,005,051           |                                   | Boehm et al.                                    | 06-1990  |   |
|                          | B7                    | JP                      | 60-252496           |                                   | ASAHI CHEM IND CO, LTD                          | 12-1985  | Abstract  |
| ✓                        | B8                    | JP                      | 03-180194           |                                   | TEIJIN LTD.                                     | 08-1991  | Abstract  |

|                    |                |                 |          |
|--------------------|----------------|-----------------|----------|
| Examiner Signature | T. Seharaleyon | Date Considered | 10/20/02 |
|--------------------|----------------|-----------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

no persons are required to report

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*Complete if Known*

|                               |                       |
|-------------------------------|-----------------------|
| <b>Application Number</b>     | 09/981,289            |
| <b>Filing Date</b>            | October 15, 2001      |
| <b>First Named Inventor</b>   | DAHIYAT, Bassil I.    |
| <b>Group Art Unit</b>         | 1647                  |
| <b>Examiner Name</b>          | J. Seharaseyn         |
| <b>Attorney Docket Number</b> | A-68990-3/RFT/RMS/RMK |

*(use as many sheets as necessary)*

|       |   |    |   |
|-------|---|----|---|
| Sheet | 2 | of | 4 |
|-------|---|----|---|

## U.S. PATENT DOCUMENTS

[illegible]

**RECEIVED**

MAY 15 2002

TECH CENTER 1600/2900

~~COPY OF PAPERS~~  
~~ORIGINALLY FILED~~

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                      | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant Figures Appear | T <sup>2</sup> |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|--|----------------|
|                    |                       | Office <sup>3</sup>     | Number <sup>4</sup> | Kind Code <sup>2</sup><br>(if known) |   |   |  |                |
| JS                 | B9                    | JP                      | 03-297388           |                                      | UBE IND LTD.                                    | 12-1991   | Abstract   |                |
|                    | B10                   | JP                      | 04-079880           |                                      | ISHIHARA SANGYO KAISHA                          | 03-1992   | Abstract   |                |
|                    | B11                   | JP                      | 04-182497           |                                      | ISHIHARA SANGYO KAISHA                          | 06-1992   | Abstract   |                |
|                    | B12                   | JP                      | 04-182498           |                                      | ISHIHARA SANGYO KAISHA                          | 06-1992   | Abstract   |                |
|                    | B13                   | JP                      | 04-368398           |                                      | ISHIHARA SANGYO KAISHA                          | 12-1992   | Abstract   |                |
|                    | B14                   | JP                      | 05-271287           |                                      | ISHIHARA SANGYO KAISHA                          | 10-1993   | Abstract   |                |
|                    | B15                   | JP                      | 05-271289           |                                      | ISHIHARA SANGYO KAISHA                          | 10-1993   | Abstract   |                |
|                    | B16                   | JP                      | 05-255393           |                                      | ISHIHARA SANGYO KAISHA                          | 10-1993   | Abstract   |                |
|                    | B17                   | WO                      | 90/07579            | A1                                   | BASF  | 07-12-1990  |  |                |
|                    | B18                   | WO                      | 94/18325            | A1                                   | N.V. INNOGENETICS                               | 08-18-1994  |  |                |
|                    | B19                   | WO                      | 98/51344            | A1                                   | KENNEDY INST.                                   | 11-19-1998  |  |                |

|                       |   |                    |  |
|-----------------------|---|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|---|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

COPY OF PAPERS  
ORIGINALLY FILED

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                        |                       |
|---|---|------------------------|-----------------------|
| Substitute for form 1449B/PTO   |   | Complete if Known      |                       |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   | Application Number     | 09/981,289            |
|   |   | Filing Date            | October 15, 2001      |
|   |   | First Named Inventor   | DAHIYAT, Bassil I.    |
|   |   | Group Art Unit         | 1645                  |
|   |   | Examiner Name          | J. Schaefer           |
| Sheet   | 3 | of                     | 4                     |
|   |   | Attorney Docket Number | A-68990-3/RFT/RMS/RMK |

RECEIVED

MAY 15 2002

TECH CENTER 1600/2900

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---|-----------------------|---|----------------|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| JS  | C1                    | ARAKAWA et al., "Alteration in folding efficiency and conformation of recombinant human tumor necrosis factor-alpha by replacing cysteines 69 and 101 with aspartic acid 69 and arginine 101," <i>Protein Eng</i> 3(8):721-724 (Aug 1990)                       |                |
|   | C2                    | BARBARA et al., "Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective," <i>Immunol Cell Biol</i> 74(5):434-443 (Oct 1996)   |                |
|   | C3                    | CEN et al., "Glycine68 to histidine73 has an important role in the function of human tumor necrosis factor alpha," <i>Biochem Mol Biol Int</i> 43(1):47-52 (Sep 1997)   |                |
|   | C4                    | CREASEY et al., "Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines," <i>Cancer Res</i> 47(1):14-149 (Jan 1987)   |                |
|   | C5                    | JONES et al., "The three-dimensional structure of tumour necrosis factor," <i>Prog Clin Biol Res</i> 349:321-327 (1990)   |                |
|   | C6                    | LOETSCHER et al., "Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors," <i>J Biol Chem</i> 268(35):26350-26357 (Dec 1993)  |                |
|   | C7                    | MASEGI et al., "Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity," <i>Jpn J Cancer Res</i> 86(1):72-80 (Jan 1995)   |                |
|   | C8                    | NARACHI et al., "Role of single disulfide in recombinant human tumor necrosis factor-alpha," <i>J Biol Chem</i> 262(27):13107-13110 (Sep 1987)  |                |
|   | C9                    | PEITSCH, M.C. and TSCHOPP, J., "Comparative molecular modelling of the Fas-ligand and other members of the TNF family," <i>Mol Immunol.</i> 1995 Jul;32(10):761-72  |                |
|   | C10                   | SATO et al., "Differentiation induction by a tumor-necrosis-factor mutant 471 in human myelogenous leukemic cells via tumor-necrosis-factor receptor-p55," <i>Int J Cancer</i> 78(2):223-232 (oct 1998)   |                |
|   | C11                   | SHIN et al., "A novel tumor necrosis factor-alpha mutant with significantly enhanced cytotoxicity and receptor binding affinity," <i>Biochem Mol Biol Int</i> 44(6):1075-1082 (May 1998)  |                |
|   | C12                   | TAVERNIER et al., "Analysis of the structure-function relationship of tumour necrosis factor. Human/mouse chimeric TNF proteins: general properties and epitope analysis," <i>J Mol Biol</i> 211(2):493-501 (Jan 1990)  |                |
|   | C13                   | VAN OSTADE, X., et al., "Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis," <i>EMBO J</i> 10(4):827-836 (1991); Erratum in <i>EMBO J</i> 11(8):315 (1992)  |                |
|   | C14                   | VAN OSTADE et al., "Structure-activity studies of human tumour necrosis factors," <i>Protein Eng</i> 7(1):5-22 (Jan 1994)   |                |
|   | C15                   | VAN OSTADE et al., "Two conserved tryptophan residues of tumor necrosis factor and lymphotoxin are not involved in the biological activity," <i>FEBS Lett</i> 238(2):347-352 (Oct 1988)   |                |

|                    |                    |                 |                 |
|--------------------|--------------------|-----------------|-----------------|
| Examiner Signature | <i>J. Schaefer</i> | Date Considered | <i>10/21/01</i> |
|--------------------|--------------------|-----------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                        |                       |
|---|---|----|---|------------------------|-----------------------|
| Substitute for form 1449B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |    |   | Complete if Known      |                       |
|   |   |    |   | Application Number     | 09/981,289            |
|   |   |    |   | Filing Date            | October 15, 2001      |
|   |   |    |   | First Named Inventor   | DAHIYAT, Bassil I.    |
|   |   |    |   | Group Art Unit         | 16437                 |
|   |   |    |   | Examiner Name          | J. Schwaninger        |
|   |   |    |   | Attorney Docket Number | A-68990-3/RFT/RMS/RMR |
| Sheet   | 4 | of | 4 |                        |                       |

[illegible]

|                       |   |                    |  |
|-----------------------|---|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|---|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

